H.R. 6, the "21st Century Cures Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
H.R. 9, the "Innovation Act," specifically those sections relating to the Inter Partes Review process.
Duration: September 1, 2013
to
September 30, 2015
General Issues: Health Issues , Copyright/Patent/Trademark , Medicare/Medicaid
Spending: about $260,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Chris Jones
Chief of Staff/Rep. Mike Ferguson
Deputy Chief of Staff/Rep. David McIntosh
Communications Dir./House Govt. Reform and Oversight Subcmte
Press Secretary/Rep. John Myers
Adam Higgins
Legislative Assistant/Rep. Mike Ferguson
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2015
Ferguson Strategies, LLC terminated an engagement in which they represented Pharmaceutical Research and Manufacturers of America on Oct. 19, 2015.
Original Filing: 300758403.xml
Lobbying Issues
H.R. 6, the "21st Century Cures Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Ferguson Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on July 17, 2015.
Original Filing: 300739635.xml
Lobbying Issues
H.R. 6, the "21st Century Cures Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, Ferguson Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300726202.xml
Lobbying Issues
21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry.
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2014
In Q4, Ferguson Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300703151.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2014
In Q3, Ferguson Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on Oct. 14, 2014.
Original Filing: 300676233.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program; Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues; and Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2014
In Q2, Ferguson Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on July 16, 2014.
Original Filing: 300657674.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Part D.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2014
In Q1, Ferguson Strategies, LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on April 19, 2014.
Original Filing: 300642924.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to
implementation of the Prescription Drug User Fee program; Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues; and Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Ferguson Strategies LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $30,000. The report was filed on Jan. 15, 2014.
Original Filing: 300614894.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to
implementation of the Prescription Drug User Fee program; Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues; and Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Medicare Part D, including rebates and non-interference.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, Ferguson Strategies LLC lobbied for Pharmaceutical Research and Manufacturers of America , earning $20,000. The report was filed on Oct. 21, 2013.
Original Filing: 300601781.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to
implementation of the Prescription Drug User Fee program; Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues; and Public Law No. 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act," specifically current policy issues relating to Part D.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
Ferguson Strategies LLC filed a lobbying registration on Sept. 12, 2013 to represent Pharmaceutical Research and Manufacturers of America, effective Sept. 1, 2013.
Original Filing: 300589810.xml
Issue(s) they said they’d lobby about: Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program; Public Law No. 111-148, the "Patiet Protection and Affordable Care Act" ; and Public Law No, 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act." .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate